WallStSmart

Merck & Company Inc (MRK)vsRoivant Sciences Ltd (ROIV)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 796123% more annual revenue ($65.77B vs $8.26M). MRK leads profitability with a 13.6% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 50/100 (D+).

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.27

ROIV

Avoid

24

out of 100

Grade: F

Growth: 2.0Profit: 2.5Value: 5.0Quality: 8.5
Piotroski: 2/9Altman Z: 8.04
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-40.6%)

Margin of Safety

-40.6%

Fair Value

$80.96

Current Price

$119.60

$38.64 premium

UndervaluedFair: $80.96Overvalued

Intrinsic value data unavailable for ROIV.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$283.78B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

ROIV2 strengths · Avg: 10.0/10
Debt/EquityHealth
0.0210/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
8.0410/10

Safe zone — low bankruptcy risk

Areas to Watch

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
32.4x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

ROIV4 concerns · Avg: 2.5/10
Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Return on EquityProfitability
-6.6%2/10

ROE of -6.6% — below average capital efficiency

Revenue GrowthGrowth
-66.7%2/10

Revenue declined 66.7%

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : ROIV

The strongest argument for ROIV centers on Debt/Equity, Altman Z-Score.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Bear Case : ROIV

The primary concerns for ROIV are Profit Margin, Piotroski F-Score, Return on Equity.

Key Dynamics to Monitor

ROIV carries more volatility with a beta of 1.14 — expect wider price swings.

MRK is growing revenue faster at 4.9% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MRK scores higher overall (50/100 vs 24/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Roivant Sciences Ltd

HEALTHCARE · BIOTECHNOLOGY · USA

Roivant Sciences Ltd (ROIV) is a pioneering biopharmaceutical company focused on transforming drug development and commercialization with its innovative business model and cutting-edge technologies. With a diverse pipeline addressing substantial unmet medical needs in areas such as neurology, immunology, and rare diseases, Roivant aims to streamline the drug development process and reduce costs significantly. The company's seasoned leadership and strategic partnerships enhance its ability to navigate the complex healthcare landscape, making it an attractive prospect for institutional investors seeking opportunities that drive both financial returns and improved patient outcomes.

Visit Website →

Want to dig deeper into these stocks?